Vibe Bioscience Ltd (VIBE) AI Stock Analysis

• Market Cap: C$593.83K
• Dividend Yield: N/A
• Average Volume (3M): 14.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.34
• Revenue Growth: 21.95%
• EPS Growth: 37.68%
• Country: CA
• Employees: 110
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 10,796,989
• 10 Day Avg. Volume: 19,833
• 30 Day Avg. Volume: 14,066
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score is primarily driven by significant financial challenges, including declining revenues and negative equity. Technical analysis indicates a bearish trend, and valuation metrics are weak due to negative earnings. These factors collectively contribute to a low overall score, highlighting the company's need for strategic improvements.

Positive Factors

Revenue Growth

The company's revenue growth indicates a positive trend in market demand for its products, suggesting potential for future expansion and increased market share.

Cash Flow Improvement

Improvement in free cash flow suggests better cash management and operational efficiency, which can support future investments and reduce financial strain.

Product Innovation

The company's focus on innovative cannabinoid-based products positions it well in the growing health and wellness market, potentially driving long-term growth.

Negative Factors

Negative Equity

Negative equity indicates solvency risks and financial instability, which can limit the company's ability to raise capital and invest in growth opportunities.

Declining Revenue

A significant decline in revenue over recent years suggests challenges in maintaining market position and competitiveness, impacting long-term viability.

Profitability Issues

Ongoing profitability challenges reflect operational inefficiencies and market pressures, which may hinder sustainable growth and shareholder value creation.

Vibe Bioscience Ltd Business Overview & Revenue Model

Company Description

Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal. The company operates five dispensaries, one distribution, and two cultivation operations, as well as sells its products through its e-commerce platform under the Vibe By California brand. It also involved in the indoor cultivation; commercial distribution and transportation; e-commerce and home delivery; and manufacturing of marijuana products. The company was formerly known as Vibe Bioscience Ltd. and changed its name to Vibe Growth Corporation in October 2020. Vibe Growth Corporation was incorporated in 2020 and is headquartered in Sacramento, California.

How the Company Makes Money

Vibe Bioscience Ltd generates revenue primarily through the sale of its cannabinoid-based products, which include oils, edibles, and wellness supplements. The company leverages its expertise in biotechnology to develop unique formulations that cater to consumer needs in the health and wellness market. Key revenue streams also include partnerships with retailers and distributors, allowing VIBE to expand its market reach. Additionally, the company may engage in research collaborations or licensing agreements with other firms in the pharmaceutical and healthcare sectors, further diversifying its income sources. The growth of the legal cannabis market and increasing consumer acceptance of cannabinoid products contribute significantly to VIBE's earnings potential.

Vibe Bioscience Ltd Financial Statement Overview

Summary

Vibe Bioscience Ltd is facing severe financial challenges, with declining revenues, persistent losses, and negative equity. The balance sheet shows high leverage and solvency risks, while cash flow improvements are insufficient to offset overall financial instability.

Income Statement

Vibe Bioscience Ltd has experienced a significant decline in revenue over the years, with a noticeable decrease from $24.2M in 2020 to $12.7M in 2024. Gross profit margins have also deteriorated, falling from 35.2% in 2020 to 37.2% in 2024. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. The net profit margin has remained negative, highlighting profitability issues. Overall, the income statement reflects a company struggling with declining revenues and persistent losses.

Balance Sheet

The balance sheet of Vibe Bioscience Ltd presents significant concerns. The company's stockholders' equity turned negative in 2024, indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, which is a red flag for leverage risk. The equity ratio has shifted from 55.1% in 2020 to negative in 2024, demonstrating weakened financial stability. Overall, the balance sheet shows a company with high liabilities and diminishing asset base, posing a risk to financial health.

Cash Flow

The cash flow statement shows some improvement in free cash flow in 2024, rising to $202,824 from a negative position in previous years. Operating cash flow turned positive in 2024, a positive sign, but the company still faces challenges with consistent negative free cash flow in past periods, indicating cash management issues. The operating cash flow to net income ratio is positive but low due to negative net income, suggesting operational cash generation struggles. Overall, the cash flow situation, while slightly improving, remains concerning.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.33M	12.71M	14.15M	20.71M	29.29M	24.24M
Gross Profit	5.21M	4.74M	5.17M	6.49M	8.42M	8.54M
EBITDA	-3.41M	-3.91M	-8.42M	-3.07M	-1.11M	3.05M
Net Income	-6.05M	-6.54M	-11.13M	-9.45M	-4.30M	728.55K
Balance Sheet
Total Assets	11.10M	11.29M	16.28M	25.89M	32.90M	18.34M
Cash, Cash Equivalents and Short-Term Investments	899.25K	1.06M	1.17M	4.55M	9.10M	2.41M
Total Debt	2.48M	2.57M	2.89M	3.38M	2.83M	2.57M
Total Liabilities	16.50M	16.51M	15.20M	13.63M	11.50M	8.23M
Stockholders Equity	-5.41M	-5.22M	1.08M	12.26M	21.39M	10.11M
Cash Flow
Free Cash Flow	-24.93K	202.82K	-2.78M	-3.71M	-7.20M	193.36K
Operating Cash Flow	10.98K	233.74K	-2.71M	-1.97M	848.73K	724.34K
Investing Cash Flow	14.02K	19.02K	-71.80K	-1.75M	-8.43M	362.35K
Financing Cash Flow	-324.14K	-360.37K	-595.55K	-699.14K	14.33M	-324.15K

Vibe Bioscience Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.64 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:VIBE.

Vibe Bioscience Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
VIBE	41 Neutral	C$593.83K	―	-201.37%	―	21.95%	37.68%
MLCL	―	C$488.91K	―		―	―	―
LRDS	―	C$577.62K	―		―	―	―
BIO	―	C$562.09K	―		―	―	―
CNTR	25 Underperform	C$347.39K	―	39.03%	―	―	―

Vibe Bioscience Ltd Corporate Events

Vibe Growth Director to Reduce Stake with Share Sale

Mark Waldron, a director at Vibe Growth Corporation, has filed an Early Warning Report indicating his intention to sell 250,000 common shares of the company through the Canadian Securities Exchange. This move will reduce Waldron’s stake from 18.14% to 15.83% of the company’s outstanding shares. The sale is part of Waldron’s strategy to decrease his holdings and utilize the proceeds for other purposes, though he remains open to future transactions based on market conditions.